Valeo Pharma Inc. (VPHIF)
OTC PINK OTC PINK Primary Summary
VPHIF Chart
Valeo Pharma adds chief development officer to drive growth initiatives
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) announced that Al Moghaddam will be taking up the newly created role of chief development officer and, as a result will be stepping down from the company's board of directors. The Canadian pharmaceutical company said that as CDO, Moghaddam will lead the design and implementation of strategies to identify and negotiate with financial parties to strengthen its capital structure.
Valeo Pharma sees record 2Q revenue boosted by respiratory products and core brand growth
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) saw revenue for the second quarter of 2024 increase primarily driven by successful promotional activities for respiratory products, increased sales of Allerject, and continued growth in other core products like Redesca and Simbrinza. In its 2Q financial statement, the Canadian pharmaceutical company posted revenues of $14.1 million, up 4% from $13.6 million in the same year-ago period.
Valeo Pharma restructures field operations to save over $5m annually
Valeo Pharma Inc said it has launched a restructuring of its field sales operations, taking cost-cutting to more than $7 million a year, including other recent measures. The latest initiative, which includes a 20% reduction of the workforce, aims to improve margins, reduce operating expenses, and accelerate the company's path to profitability.
Valeo Pharma Inc. (VPHIF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Valeo Pharma Inc. ever had a stock split?
Valeo Pharma Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Kyle Steiger CEO | OTC PINK Exchange | 91915B108 CUSIP |
| CA Country | 70 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Valeo Pharma Inc. is a specialty pharmaceutical company founded in 2003, with its headquarters located in Kirkland, Canada. The company focuses on the acquisition, licensing, and sale of pharmaceutical products primarily in the Canadian market. Valeo Pharma specializes in a niche array of product categories including respiratory diseases, specialty and hospital generic products. The company’s efforts are directed towards improving patient care and offering effective solutions for various health concerns through its diversified product portfolio.
Products and Services
- Enerzair Breezhaler: A LABA/LAMA/ICS fixed triple dose inhaler designed for patients with asthma. It represents an advanced treatment option aiming to improve lung function and reduce the frequency of asthma attacks.
- Atectura Breezhaler: This LABA/ICS dual combination asthma drug helps in managing and preventing asthma symptoms, offering a simplified treatment regime for better patient adherence.
- Redesca: A generic version that’s indicated for the treatment and prevention of deep vein thrombosis and pulmonary embolism, offering an essential option for vascular health management.
- Onstryv: Focused on enhancing the quality of life for patients with Idiopathic Parkinson's Disease (PD), Onstryv is used as an add-on therapy for those on stable doses of Levodopa, alone or in combination with other drugs.
- M-Eslon: An extended-release morphine sulphate designed for pain management. M-Eslon provides enduring relief for patients enduring chronic pain, ensuring a stable quality of life.
- Yondelis: It targets soft tissue sarcoma, providing a treatment option for this rare type of cancer. Yondelis contributes to the limited arsenal against such challenging conditions.
- Hesperco: A bioflavonoid antioxidant used for immune support. In the wake of increasing health consciousness, Hesperco offers a natural option for bolstering the body's defense system against illnesses.
- Ametop: Provides skin anesthesia prior to venepuncture or venous cannulation. Ametop is crucial for reducing procedural discomfort and pain in medical settings.
- Benztropine: An anticholinergic agent for the treatment of PD, Benztropine plays a fundamental role in managing neurological symptoms and improving patient outcomes.
- Ethacrynate Sodium: A loop diuretic used for treating high blood pressure and the swelling associated with it. It is vital for managing cardiovascular conditions and preventing complications.
- Amikacin: An injectable antibiotic used to treat severe or resistant infections. As antibiotic resistance continues to rise, Amikacin offers a crucial option for treating life-threatening bacterial infections.
